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THE BELGIAN REIMBURSEMENT PROCEDURE (BRP):ARE
ADDEDTHERAPEUTICVALUE (ATV) AND ICER AFFECTING
THE DRUG REIMBURSEMENT DECISION (DRD)?
Verplanken P1,Arickx F1, Bormans V1, Soete E1,Annemans L2,
Robays H3,Van Wilder P1
1RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium,
2University of Ghent, Brussels University, Ghent, Belgium, 3Ghent
University, Grimbergen, Belgium
OBJECTIVES: Since 2002, the BRP for medicinal products
claiming ATV requires the evaluation of the therapeutic and
pharmaco-economic value as compared to alternatives. The
study aim was to analyze the effect of ATV and ICER on the
DRD. METHODS: The RIZIV administrative database was used
for extracting all ﬁles claiming ATV submitted between January
2002 and February 2008. ICERs expressed per QALY or per
LYG were pooled. ATV was a binary outcome variable (ATV
either present or absent). The DRD was either positive or nega-
tive. Statistical analysis (logistic regression /backwards elimina-
tion) was performed using SAS EG. The signiﬁcance level was set
at 0.05. Only complete cases were analyzed. RESULTS: A total
of 138 submissions fulﬁlled the criteria. Data were available for
all variables in only 76 (55.1%) cases. ATV and ICER were both
signiﬁcantly (p < 0.01) related with the ﬁnal DRD. The odds of a
positive DRD increase to 9.5-fold if ATV was granted and
decrease to 0.45-fold if the ICER increases €10,000. No signiﬁ-
cant interactions were observed (p > 0.10). CONCLUSIONS:
Based on this sample, our analysis indicates that both ATV and
ICER have a prognostic (but opposite) effect on the ﬁnal DRD in
Belgium. Further investigation should consider the potential
effects of other variables such as budget impact, disease category,
price and others on the DRD.
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MARKET AUTHORIZATION (MA) AND REIMBURSEMENT:
ANALYSIS OFTHE POST-MATIMELINES ANDTHE ACCESSTO
NEW MEDICINES IN BELGIUM
Arickx F, Pierlet M, Soete E,VanHaeren E,Verplanken P,
Van Wilder P
RIZIV INAMI National Health Insurance Agency, Brussels, Belgium
OBJECTIVES: The study aim was to investigate the time delays
between market authorization, reimbursement submission and
reimbursement authorization and to analyze whether the type of
submission affects these delays for new products. METHODS:
Data were extracted from the Riziv administrative database. A
total of 613 reimbursement ﬁles were handled between January
1, 2002 and December 31, 2007. The three submission types
were: added (n = 104) or similar (n = 480) therapeutic value or
orphan status (n = 29). The following variables were computed:
TTS = time between market authorization and reimbursement
submission; TSA = time between reimbursement submission and
authorization; TMR = time between market authorization and
reimbursement authorization. Resubmissions of unapproved
claims were excluded to maintain the independency between
ﬁles. All statistical analyses were executed in SAS EG. RESULTS:
The median (25th–75th percentile)delays (in days) were respec-
tively 137 (46–308), 258 (235–294) and 421 (307–633) for
TTS, TSA and TMR. There was no signiﬁcant difference in
TTS (p = 0.11) between submission types: TSA and TMR were
signiﬁcantly longer (p < 0.05) respectively for added value and
orphan submissions as compared to claims for similar value.
CONCLUSIONS: The median delay between marketing autho-
rization and actual reimbursement of new medicines is 421 days
in the 2002–2007 period. However the local applicant needs a
median of 137 days before a reimbursement claim is submitted:
the reimbursement process needs a median of 258 days between
submission and authorization, overestimating the time needed
because it includes any suspension period requested by the appli-
cant during the procedure. There was no signiﬁcant difference in
TTS between submission types indicating that the need for
pharmaco-economic data for added value claims is not jeopar-
dizing TTS. TSA for added value and TMR for orphan submis-
sions were signiﬁcantly longer indicating the more complex
evaluation process which precedes the reimbursement decision.
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THE COMPETITIVE ACQUISITION PROGRAM (CAP):
WHERE IS IT AFTERTWOYEARS?
Pierce CA
The Resource Group, Richﬁeld, OH, USA
OBJECTIVES: Since 2006 physicians have been able to select the
competitive drug acquisition program (CAP) as an alternative
method of acquiring drugs and biologics for in-ofﬁce adminis-
tration under Medicare. This study examines the evolution of
the program from 2006 to present, recounts the legislative and
regulatory program impacts and describes issues that remain
as potential obstacles to widespread provider acceptance.
METHODS: Historic CAP regulatory and legislative guidance
was collected, arranged in order of issuance, abstracted and
analyzed. A timeline illustrating evolutionary program modiﬁca-
tions was constructed. Remaining issues that may deter provider
participation were described and information resources were
compiled. RESULTS: The CAP is a payment model that removes
the drug purchasing function from the physician’s ofﬁce while the
drug administration responsibility remains. Despite intent to
minimize provider ﬁnancial risk and ease operational burden, the
CAP has been slow to attract participants. There have been
legislative and regulatory attempts to modify and improve the
program’s attractiveness and ease of use however the majority of
physicians providing in-ofﬁce drugs continue to do so through
conventional buy and bill methods. Throughout this time the
Medicare drug payment to physician ofﬁces has remained at
average sales price plus six percent (ASP +6%) and the associated
drug administration rates have been fairly stable. CONCLU-
SIONS: The number of providers utilizing the buy and bill
method was expected to decrease following implementation of
the CAP alternative. The CAP program has now been in effect for
over two years, has undergone a number of operational modiﬁ-
cations, and yet continues to experience low enrollment. At this
time it is not possible to determine conclusively the impact of: 1)
inadequate provider incentive to drive the conversion, or 2) the
deterrent effect of remaining program issues. Further investiga-
tion is warranted.
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OBJECTIVES: To identify characteristics of the individual that
may predict pharmaceutical use. We study the impact of socio-
demographic (gender, age, marital status, education, rural/urban
residence) and need factors (chronic diseases, health-related
quality of life, measured by the Greek version of SF-12, previous-
year physician consultations and hospitalizations). METHODS:
Data was obtained from a nationally representative sample
(N = 1005) of the general-non-institutionalized-population in
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Greece. The study was carried out in 2006 and participants were
face-to-face interviewed to report on their use of pharmaceuticals
and on the number of pharmaceuticals taken in a speciﬁed recent
period. Multivariable logistic regression analysis was performed
to ascertain the predictive factors of the pharmaceutical con-
sumption. Statistical signiﬁcance was accepted at the 5% level.
RESULTS: A total of 43.7% of the sample had used pharmaceu-
ticals. Age, chronic diseases, HRQoL, number of physician
consultations and hospitalization were best predictors of phar-
maceutical use. Factors associated with higher likelihood of using
pharmaceuticals were elderly people (exp(b) = 1.72, CI:1.51–
1.70), chronic diseases (exp(b) = 6.61, CI:3.39–9.96), poorer
HRQOL (PSC12 exp(b) = 0.93, CI:0.90–0.95, MCS12
exp(b) = 0.97, CI:0.93–0.99) and number of physician consulta-
tions during the last year (exp(b) = 3.05, CI:1.96–4.76). On the
other hand, taking four or more pharmaceuticals concurrently
were best predicted by older age (exp(b) = 1.52, CI:1.11–2.09),
chronic diseases (exp(b) = 3.84, CI: 1.58–5.94), poorer HRQOL
(PCS12 exp(b) = 0.95, CI:0.92–0.97, MCS12 exp(b) = 0.95, CI:
0.93–0.98), number of physician consultations during the year
(exp(b) = 3.59, CI: 1.36–5.41) and hospitalization during the last
year (exp(b) = 2.13, CI:1.13–4.02). CONCLUSIONS: Pharma-
ceutical use is related to population aging (combined with
chronic disease) a fact that should be a cause of concern in the
future, taking into account the demographic problem in the
western societies.
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Tomic Z1, Sabo A1,Vukmirovic S1, Milijasevic B1, Satman M2,
Golocorbin Kohn S1, Mikov M1
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OBJECTIVES: The aim of this research was to analyze outhospi-
tal drug consumption in Montenegro in 2007, and to compare
data with drug consumption in previous period. The aim was also
to compare drug consumption in Montenegro with drug con-
sumption in countries with developed prarmacotherapeutic prac-
tice. METHODS: Drug consumption was analyzed by number of
DDD per 1000 inhabitants per day. Consumption of ﬁnancial
resources was analyzed as well. RESULTS: Total outhospital drug
consumption funded by Republic Health Fund of Montenegro in
2007. was 278.59 DDD/1000 inhabit./day. The highest consump-
tion was in group C (drugs for cardiovascular diseases) with
149.29 DDD/1000 inhabit./day (53.59% of total drug consump-
tion). Second highest consumption was in group A (drugs for
alimentary tract andmetabolism)with 34.67 DDD/1000 inhabit./
day (12.45% of total drug consumption). Drugs for nervous
system participated with 10.50% in total drug consumption with
29.25 DDD/1000 inhabit./day. Total drug consumption funded
by Republic Health Fund of Montenegro in 2007. was increased
for 36.68% compared to drug consumption in 2005.
(203.82 DDD/1000 inhabit./day). Increase in drug consumption
resulted in increased consumption of ﬁnancial resources
(12.859.961.58 €) which were higher for 2.857.855.73 € then in
2005. Highest increase in consumption of ﬁnancial resources was
in group C (€1,096.468.28 in 2007.), group A (€559,827.80
in 2007.), group R (€468,156.55 in 2007.) and group N
(€452,212.30 in 2007.). CONCLUSIONS: Although there was a
signiﬁcant decrease in drug consumption in Montenegro in 2007.
compared to 2005. drug consumption in 2007. was much lower
then in Scandinavian countries. Detailed analysis in separate ATC
groups of drugs reveal that consumption is not always rational
from pharmacoterapeutic and pharmacoeconomic point of view.
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SOURCES OF INFORMATION ON DRUGS USED BY GENERAL
PRACTITIONERS IN POLAND
Ułanowski P, Jakubczyk M, Hermanowski T
Department of Pharmacoeconomics, Medical University of Warsaw,
Warsaw, Poland
OBJECTIVES: To identify most frequently used and most inﬂu-
ential sources of information on drugs in Poland, as well as to
determine their credibility as perceived by GPs’ and possible
factors limiting access to these sources. METHODS: An anony-
mous survey was conducted among one hundred GPs in ambu-
latories in Warsaw, Poland. GPs were questioned about the
sources of information used in the past six months and frequency
of usage. GPs were also asked to divide 100 pts to indicate the
most important limitations in access to sources, the perceived
credibility of the sources and the sources inﬂuencing the decision
most. Demographic questions were included. RESULTS:
[UNKNOWN NODETYPE 9] Only 25% GPs considered them-
selves limited in the access to drug information, while 69%
believed the information was sufﬁcient. The most frequent bar-
riers referred to GPs themselves: lack of foreign language skills
(average of 24.7 points); money limitations (22.4), lack of time
(20.87 pts), no EBM competency (20.6). There is a statistically
signiﬁcant (all tests for a = 0.05) negative relation between usage
and perceived limitations. Younger GPs perceived lack of infor-
mation statistically signiﬁcantly more often (Fisher’s exact test).
The sources that were most frequently used in the past 6 months
were: drug directories (96% GPs), pharmaceutical companies
representatives (93%), polish professional journals (92.6%).
High importance of commercial sources conﬁrmed previous
results of POLKARD-SPOK survey in Poland and agrees with
results of surveys in other countries. On the other hand the SPOK
survey showed higher role of Polish professional journals. GPs
declared that drug selection is inﬂuenced most by medical jour-
nals (29.16 pts), medical books (24.93), and information from
pharmaceutical companies representatives (21.15). There is a
slight discrepancy between usage and inﬂuence, which may
suggest an element of wishful thinking. CONCLUSIONS: Rela-
tively few GPs feel insufﬁciently informed. Whether this is an
objective (i.e. results from their proﬁciency) or subjective fact (i.e.
results from their lack of knowledge of information gap) should
be a matter of further studies. Information gained from pharma-
ceutical companies representatives is an important factor both in
terms of frequency and impact on decisions. Confronting this
with limitations of GPs in gathering new information by them-
selves proves there is a need for EBM popularization in Poland.
PHP18
COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND
THERAPEUTIC DEVICES OR DRUGS
Rodríguez Bezos D, Serrano D, Rodríguez Barrios JM
Medtronic Iberica, Madrid, Madrid, Spain
OBJECTIVE: In the last years, economic evaluations with
quality adjusted life year (QALY) as effectiveness variable
increased. Cost-utility analyses are generally preferred by health
care policy makers and payers, because include both quality and
quantity of life. Also, QALY allows comparing different inter-
ventions with the same evaluation unit. The majority of eco-
nomic studies evaluate drugs, despite of increment of diagnostic
and therapeutic devices studies in the last years. The main objec-
tive consists on a comparison of Cost/QALY ratio in diagnostic
and therapeutic devices with drug treatments in studies devel-
oped in the Spanish setting in the last 12 years. METHOD: A
Spanish cost-effectiveness and cost-utility studies review was
developed, including all published studies during the last 12
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